{
    "clinical_study": {
        "@rank": "18401", 
        "arm_group": [
            {
                "arm_group_label": "Creon", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "maldigestion of dietary macronutrients (pancreas not producing enough enzymes for digestion\n      of fat, sugars and proteins) in diabetes type II"
        }, 
        "brief_title": "A Study to Assess the Effect of Creon\u00ae on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Exocrine Pancreatic Insufficiency in Subjects With Diabetes Mellitus Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Exocrine Pancreatic Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed Informed Consent\n\n          -  BMI < 30 kg/m2\n\n          -  History of type 2 diabetes mellitus as confirmed by:\n\n          -  onset of diabetes after 30 years of age and\n\n          -  no insulin treatment in the first year after diagnosis\n\n          -  Subjects on insulin treatment or on insulin treatment in combination with oral\n             antidiabetics\n\n          -  HbA1c > 6.5% in medical history within the last 6 months despite insulin treatment\n\n          -  Not previously treated with any pancreatic enzyme supplementation\n\n        Inclusion Criterion at Visit 1:\n\n        \u2022 FE-1 (fecal elastase 1) <100\u03bcg/g of stool\n\n        Inclusion Criterion at Visit 2:\n\n        \u2022 13C MTBT of <29% 13CO2-CRR (Carbon dioxide-Cumulative Recovery Rate)\n\n        Exclusion Criteria:\n\n          -  Treatment with systemic steroids for at least 3 weeks within past 6 months\n\n          -  Patients with a known pancreatic exocrine insufficiency due to non-diabetic diseases,\n             e.g., chronic pancreatitis, pancreatectomy, cystic fibrosis, celiac disease,\n             shwachman-diamond syndrome, gastrectomy, etc.\n\n          -  Any type of malignancy involving digestive tract in the last 5 years\n\n          -  Any type of gastrointestinal surgery (except appendectomy and gallbladder resection)\n\n          -  Short bowel syndrome\n\n          -  Hemochromatosis\n\n          -  Known late onset autoimmune diabetes in the adult\n\n          -  Any history of drug abuse including alcohol\n\n          -  Positive urine pregnancy test; lactation; females of child-bearing potential who are\n             not using either an oral hormonal contraceptive or an intrauterine device\n\n          -  Hypersensitivity to the active substance or to any of the excipients\n\n          -  Intake of an experimental drug within 4 weeks prior to entry into this study\n\n          -  Suspected non-compliance or non-cooperation\n\n          -  History of human immunodeficiency virus (HIV) infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02009410", 
            "org_study_id": "M13-954", 
            "secondary_id": "2013-001347-31"
        }, 
        "intervention": [
            {
                "arm_group_label": "Creon", 
                "description": "Creon 25000 (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks", 
                "intervention_name": "Creon", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Creon 25000 placebo matching capsules (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks", 
                "intervention_name": "Creon 25000 matching Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pancreatin", 
                "Pancrelipase"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Exocrine Pancreatic Insufficiency", 
        "lastchanged_date": "March 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bochum", 
                        "country": "Germany", 
                        "zip": "44789"
                    }, 
                    "name": "Site reference no. 113456"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany", 
                        "zip": "60594"
                    }, 
                    "name": "Site reference no. 113477"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pohlheim", 
                        "country": "Germany", 
                        "zip": "35415"
                    }, 
                    "name": "Site reference no. 113476"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ulm", 
                        "country": "Germany", 
                        "zip": "89073"
                    }, 
                    "name": "Site reference no. 113475"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28034"
                    }, 
                    "name": "Site reference no. 112519"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00e1laga", 
                        "country": "Spain", 
                        "zip": "29071"
                    }, 
                    "name": "Site reference no. 112520"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santiago de Compostela", 
                        "country": "Spain", 
                        "zip": "15706"
                    }, 
                    "name": "Site reference no. 112495"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Segovia", 
                        "country": "Spain", 
                        "zip": "40002"
                    }, 
                    "name": "Site reference no. 112518"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "zip": "41014"
                    }, 
                    "name": "Site reference no. 112496"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "\u00c1vila", 
                        "country": "Spain", 
                        "zip": "05004"
                    }, 
                    "name": "Site reference no. 112517"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Spain"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Assess the Effect of Creon\u00ae on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2", 
        "other_outcome": [
            {
                "description": "blood pressure and heart rate, body weight and BMI", 
                "measure": "vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "from baseline up to the week 12 visit"
            }, 
            {
                "description": "Hematology, biochemistry and a urine pregnancy test will be performed", 
                "measure": "routine safety laboratory", 
                "safety_issue": "Yes", 
                "time_frame": "from baseline up to the week 12 visit"
            }
        ], 
        "overall_contact": {
            "email": "hanneke.vanassche@abbott.com", 
            "last_name": "Hanneke van Assche", 
            "phone": "+31 (0)294 47", 
            "phone_ext": "7367"
        }, 
        "overall_contact_backup": {
            "email": "suntje.sander@abbott.com", 
            "last_name": "Suntje Sander-Struckmeier", 
            "phone": "+49 (0) 511 6750", 
            "phone_ext": "3254"
        }, 
        "overall_official": {
            "affiliation": "Abbott", 
            "last_name": "Suntje Sander-Struckmeier, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Recovery rate of 13CO2 (carbon dioxide with stable isotope of carbon)", 
            "safety_issue": "No", 
            "time_frame": "from baseline up to the week 12 visit"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02009410"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "fat soluble vitamins (D and E), retinol-binding protein, albumin, pre-albumin, magesium and calcium will be measured.", 
                "measure": "Change in nutritional parameters", 
                "safety_issue": "No", 
                "time_frame": "from baseline up to the week 12 visit"
            }, 
            {
                "measure": "Change in HbA1c", 
                "safety_issue": "No", 
                "time_frame": "from baseline up to the week 12 visit"
            }, 
            {
                "measure": "Change in quality of life assessed via a questionnaire Gastrointestinal-Quality of Life Index (GIQL)", 
                "safety_issue": "No", 
                "time_frame": "from baseline up to the week 12 visit"
            }, 
            {
                "description": "disease symptoms will be rated by the subject according a rating scale", 
                "measure": "Change in clinical global impression of disease symptoms", 
                "safety_issue": "No", 
                "time_frame": "from baseline up to the week 12 visit"
            }
        ], 
        "source": "Abbott", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Nuvisan", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Datamap", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "ClinIntel", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Catalent", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Abbott", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}